Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

p53 and ras mutations in Ewing's sarcoma

K Radig1, R Schneider-Stock, I Röse

  • 1Department of Pathology, Otto-von-Guericke-University, Magdeburg, Germany.

Pathology, Research and Practice
|May 20, 1998
PubMed
Summary

Tumor suppressor gene mutations are rare in Ewing sarcoma (ES). This study found p53 gene mutations in only one case and no ras gene mutations, suggesting a group-specific characteristic for neuroectodermal tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Bone tumours].

Der Pathologe·2020
Same author

[Narrow band imaging for evaluation of laryngeal mucosal lesions].

HNO·2017
Same author

Articulating polymethylmethacrylate (PMMA) spacers may have an immunomodulating effect on synovial tissue.

The bone & joint journal·2016
Same author

[Inaugural speech of the congress president of the German Society of Pathology at the 98th annual congress].

Der Pathologe·2014
Same author

[98th Annual Conference of the German Society for Pathology : Berlin, 12-15 June 2014].

Der Pathologe·2014
Same author

BRCA1 promoter methylation is a marker of better response to platinum-taxane-based therapy in sporadic epithelial ovarian cancer.

Journal of cancer research and clinical oncology·2014

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The roles of tumor suppressor genes and oncogenes in Ewing sarcoma (ES) development require further clarification.
  • Understanding these genetic alterations is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the frequency of p53 tumor suppressor gene mutations and p53-protein expression in ES.
  • To analyze MDM2 overexpression, a functional p53 inactivator.
  • To screen for mutations in hot spot regions of ras-genes (H-ras, N-ras, K-ras).

Main Methods:

  • Polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and direct sequencing for p53 gene mutation analysis.
  • Immunohistochemistry to assess p53-protein and MDM2 expression.

Related Experiment Videos

  • Screening for point mutations in ras-genes.

    • Main Results:

    • A p53 gene mutation was identified in one out of 24 ES cases (codon 238, exon 7).
    • MDM2 overexpression was observed in five cases.
    • No mutations were detected in the screened ras-genes.
    • Mutations in p53 and ras genes are rare in ES compared to osteosarcomas.

    Conclusions:

    • The low incidence of p53 and ras mutations in ES is comparable to PNET (primitive neuroectodermal tumors).
    • This suggests a potential group-specific characteristic for tumors of neuroectodermal origin.
    • Further research into the genetic landscape of ES is warranted.